Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regen BioPharma (RGBP) Return on Assets (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Return on Assets for 12 consecutive years, with 2.97% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Assets rose 293.0% to 2.97% in Q4 2025 year-over-year; TTM through Dec 2025 was 2.97%, a 293.0% increase, with the full-year FY2025 number at 5.85%, down 325.0% from a year prior.
  • Return on Assets was 2.97% for Q4 2025 at Regen BioPharma, up from 5.41% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.22% in Q2 2021 to a low of 5.89% in Q4 2024.
  • A 5-year average of 2.45% and a median of 2.12% in 2023 define the central range for Return on Assets.
  • Peak YoY movement for Return on Assets: surged 1249bps in 2021, then crashed -430bps in 2024.
  • Regen BioPharma's Return on Assets stood at 0.45% in 2021, then crashed by -271bps to 1.68% in 2022, then increased by 5bps to 1.6% in 2023, then crashed by -269bps to 5.89% in 2024, then surged by 50bps to 2.97% in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Return on Assets are 2.97% (Q4 2025), 5.41% (Q3 2025), and 5.31% (Q2 2025).